Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24


Guidelines to improve animal study design and reproducibility for Alzheimer's disease and related dementias: For funders and researchers.

Snyder HM, Shineman DW, Friedman LG, Hendrix JA, Khachaturian A, Le Guillou I, Pickett J, Refolo L, Sancho RM, Ridley SH.

Alzheimers Dement. 2016 Nov;12(11):1177-1185. doi: 10.1016/j.jalz.2016.07.001.


A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline.

Dacks PA, Armstrong JJ, Brannan SK, Carman AJ, Green AM, Kirkman MS, Krakoff LR, Kuller LH, Launer LJ, Lovestone S, Merikle E, Neumann PJ, Rockwood K, Shineman DW, Stefanacci RG, Velentgas P, Viswanathan A, Whitmer RA, Williamson JD, Fillit HM.

Alzheimers Res Ther. 2016 Aug 20;8:33. doi: 10.1186/s13195-016-0200-3. Review.


Expert consensus document: Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions.

Carman AJ, Ferguson R, Cantu R, Comstock RD, Dacks PA, DeKosky ST, Gandy S, Gilbert J, Gilliland C, Gioia G, Giza C, Greicius M, Hainline B, Hayes RL, Hendrix J, Jordan B, Kovach J, Lane RF, Mannix R, Murray T, Seifert T, Shineman DW, Warren E, Wilde E, Willard H, Fillit HM.

Nat Rev Neurol. 2015 Apr;11(4):230-44. doi: 10.1038/nrneurol.2015.30. Epub 2015 Mar 17. Review.


Overcoming obstacles to repurposing for neurodegenerative disease.

Shineman DW, Alam J, Anderson M, Black SE, Carman AJ, Cummings JL, Dacks PA, Dudley JT, Frail DE, Green A, Lane RF, Lappin D, Simuni T, Stefanacci RG, Sherer T, Fillit HM.

Ann Clin Transl Neurol. 2014 Jul;1(7):512-8. doi: 10.1002/acn3.76. Epub 2014 Jun 24.


Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease.

Carman AJ, Dacks PA, Lane RF, Shineman DW, Fillit HM.

J Nutr Health Aging. 2014 Apr;18(4):383-92. doi: 10.1007/s12603-014-0021-7. Review.


Dementia Prevention: optimizing the use of observational data for personal, clinical, and public health decision-making.

Dacks PA, Andrieu S, Blacker D, Carman AJ, Green AM, Grodstein F, Henderson VW, James BD, Lane RF, Lau J, Lin PJ, Reeves BC, Shah RC, Vellas B, Yaffe K, Yurko-Mauro K, Shineman DW, Bennett DA, Fillit HM.

J Prev Alzheimers Dis. 2014 Feb;1(2):117-123.


Developing novel blood-based biomarkers for Alzheimer's disease.

Snyder HM, Carrillo MC, Grodstein F, Henriksen K, Jeromin A, Lovestone S, Mielke MM, O'Bryant S, Sarasa M, Sjøgren M, Soares H, Teeling J, Trushina E, Ward M, West T, Bain LJ, Shineman DW, Weiner M, Fillit HM.

Alzheimers Dement. 2014 Jan;10(1):109-14. doi: 10.1016/j.jalz.2013.10.007. Review.


Progress in novel cognitive enhancers for cognitive aging and Alzheimer's disease.

Shineman DW, Carman AJ, Dacks PA, Lane RF, Fillit HM.

Alzheimers Res Ther. 2013 Oct 2;5(5):45. doi: 10.1186/alzrt209. eCollection 2013.


Optimizing the use of CROs by academia and small companies.

Lane RF, Friedman LG, Keith C, Braithwaite SP, Frearson JA, Lowe DA, Longo FM, Refolo LM, Watterson DM, Tsaioun K, Shineman DW, Fillit HM.

Nat Rev Drug Discov. 2013 Jul;12(7):487-8. doi: 10.1038/nrd4057. No abstract available.


Current evidence for the clinical use of long-chain polyunsaturated n-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease.

Dacks PA, Shineman DW, Fillit HM.

J Nutr Health Aging. 2013 Mar;17(3):240-51. doi: 10.1007/s12603-012-0431-3.


Beyond amyloid: the future of therapeutics for Alzheimer's disease.

Lane RF, Shineman DW, Steele JW, Lee LB, Fillit HM.

Adv Pharmacol. 2012;64:213-71. doi: 10.1016/B978-0-12-394816-8.00007-6. Review.


Beyond amyloid: a diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias.

Lane RF, Shineman DW, Fillit HM.

Alzheimers Res Ther. 2011 Dec 15;3(6):36. doi: 10.1186/alzrt99.


Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies.

Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, Lincecum J, Leblanc GG, Lee LB, Luo F, Morgan D, Morse I, Refolo LM, Riddell DR, Scearce-Levie K, Sweeney P, Yrjänheikki J, Fillit HM.

Alzheimers Res Ther. 2011 Sep 28;3(5):28. doi: 10.1186/alzrt90.


An analysis of global research funding for the frontotemporal dementias: 1998-2008.

Walentas CD, Shineman DW, Horton AR, Boeve BF, Fillit HM.

Alzheimers Dement. 2011 Mar;7(2):142-50. doi: 10.1016/j.jalz.2010.11.010. Epub 2011 Jan 26.


Therapeutics for cognitive aging.

Shineman DW, Salthouse TA, Launer LJ, Hof PR, Bartzokis G, Kleiman R, Luine V, Buccafusco JJ, Small GW, Aisen PS, Lowe DA, Fillit HM.

Ann N Y Acad Sci. 2010 Apr;1191 Suppl 1:E1-15. doi: 10.1111/j.1749-6632.2010.05532.x.


Alzheimer's disease drug discovery: Abeta and beyond.

Shineman DW, Fillit HM.

Curr Alzheimer Res. 2010 May;7(3):188-9. No abstract available.


A multi-targeted approach for a complex multifaceted disease.

Shineman DW, Fillit HM.

Curr Alzheimer Res. 2009 Oct;6(5):407-8. No abstract available.


Novel strategies for the prevention of dementia from Alzheimer's disease.

Shineman DW, Fillit HM.

Dialogues Clin Neurosci. 2009;11(2):129-34. Review.


Meeting the unique challenges of drug discovery for neurodegenerative diseases.

Shineman DW, Fillit HM.

BMC Neurol. 2009 Jun 12;9 Suppl 1:I1. doi: 10.1186/1471-2377-9-S1-I1. No abstract available.


Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 mice.

Shineman DW, Zhang B, Leight SN, Pratico D, Lee VM.

J Neurosci. 2008 Apr 30;28(18):4785-94. doi: 10.1523/JNEUROSCI.0684-08.2008.


Role for Akt3/protein kinase Bgamma in attainment of normal brain size.

Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, Lee VM, Szabolcs M, de Jong R, Oltersdorf T, Ludwig T, Efstratiadis A, Birnbaum MJ.

Mol Cell Biol. 2005 Mar;25(5):1869-78.

Supplemental Content

Loading ...
Support Center